The antidepressant drug Paxil (paroxetine) was introduced as a therapeutic option for the treatment of depression, in the 1980s [
]. This is an effective drug that helps to relieve anxiety, but has a lower risk of abuse and addiction [
The antidepressant drug paroxetine was approved for the treatment of depression in the 1990s, however, the drug was associated with adverse effects such as insomnia and increased risk of suicide [
The risk of these adverse effects may be reduced by lifestyle changes or other drugs that affect the central nervous system, such as the antipsychotic drugs atypoclomine and risperidone [
Paroxetine has also been shown to cause neuroleptic malignant syndrome [
], which is more likely to occur in patients with psychiatric disorders. Some of the patients with psychiatric disorders may be at higher risk for the development of neuroleptic malignant syndrome, which may include those with bipolar or depressive disorders. The risk of neuroleptic malignant syndrome may increase with the dosage of this drug and with the duration of treatment, as well as with other drugs that affect serotonin [
The risk of serotonin syndrome has also been associated with use of other antipsychotics [
,
Serotonin syndrome is a type of toxicity caused by the increased release of serotonin, which results in excessive serotonin accumulation in the brain. Serotonin syndrome has also been reported in association with use of the following drugs: lithium, carbamazepine, lithium/paliperidone, phenytoin, and phenobarbital [
Antipsychotics are commonly used for the treatment of depression, but the risk of neuroleptic malignant syndrome associated with these agents is much higher. Serotonin syndrome is a potential risk factor for the development of neuroleptic malignant syndrome, which has been observed in patients who have an increased risk of developing this condition [
The risk of neuroleptic malignant syndrome may be increased by concurrent use of certain anti-depressants or monoamine oxidase inhibitors (MAOIs), such as phenytoin. However, there is evidence that the risk of serotonin syndrome is also increased by use of certain MAOIs. The risk of serotonin syndrome has also been increased with the use of selective serotonin reuptake inhibitors (SSRIs) and the use of a non-selective serotonin reuptake inhibitor (SSRI). These agents have also been reported to increase the risk of serotonin syndrome, which may be associated with concomitant use of the following agents [
]:
The risk of serotonin syndrome has been demonstrated with the use of certain anti-depressants and MAOIs, such as lithium, carbamazepine, and phenytoin [
It is likely that patients who are taking other drugs or taking MAOIs should be prescribed other drugs. The risk of serotonin syndrome in the elderly may be greater with the use of selective serotonin reuptake inhibitors (SSRIs) [
], and the risk of serotonin syndrome in the elderly may be greater with the use of these agents. The risk of serotonin syndrome may increase with the dosage of this drug and with the duration of treatment, as well as with other drugs that affect the central nervous system, such as the antipsychotic drugs atypoclomine and risperidone [
In addition to serotonin syndrome, other drugs have also been associated with serotonin syndrome [
], and may be associated with serotonin syndrome [
The risk of serotonin syndrome increases with the dosage of this drug and with the duration of treatment, as well as with other drugs that affect serotonin [
The risk of serotonin syndrome may increase with the duration of treatment, as well as with other drugs that affect serotonin [
The risk of serotonin syndrome may increase with the dosage of this drug and with the duration of treatment, as well as with other drugs that affect serotonin [
Pharmacological approaches to the treatment of depression are well-established.
Uses :
Paxil is used to treat depression (depression-like disorder) and to reduce anxiety (reducing stress in people with anxiety disorders). It may also be used for obsessive-compulsive disorder (OCD).
This study evaluated the effectiveness of Paxil (paroxetine) in the treatment of depression and anxiety disorders.
Study Design :
Trial Registration :
Name of Participants :
Study Population :
Patients who were taking Paxil (paroxetine) for depression or anxiety in the last three months of the study. Patients who were taking Paxil for depression or anxiety who were taking Paxil for anxiety before the study was stopped.
Trial was designed as a double-blind, randomized controlled trial. Patients were randomised to receive Paxil (paroxetine) (n = 11) or placebo (n = 9) for three months before randomisation. The trial was conducted in accordance with the Good Clinical Practice (GCP) guidelines, and all patients had to meet the diagnostic criteria for major depressive disorder and have at least one major depressive episode during treatment.
Intervention :
Patients were randomly assigned to take Paxil (paroxetine) (n = 11) or placebo (n = 9) in a 1:1 ratio. The patients were instructed to stop taking Paxil (paroxetine) (n = 9) and to start taking Paxil (paroxetine) (n = 11) after three months of treatment. Patients who had taken Paxil (paroxetine) (n = 9) or placebo (n = 11) for the previous three months and who had not yet been evaluated in the study had to stop taking Paxil (paroxetine) (n = 9) and start taking Paxil (paroxetine) (n = 11).
Outcomes :
The primary efficacy parameter was the reduction in the number of depressive symptoms (including time to complete remission, number of episodes of depression, number of episodes of major depressive disorder), time to major depressive disorder, time to recurrence of depression, number of major depressive episodes, number of depressive episodes and number of depressive episodes per patient. Secondary efficacy parameters were the number of recurrences and recurrence of depression. The primary safety parameter was the change in the total number of major depressive episodes, time to recurrence of depression, number of depressive episodes per patient.
The patients were instructed to stop taking Paxil (paroxetine) (n = 9) and start taking Paxil (paroxetine) (n = 11).
The primary efficacy parameter was the change in the number of recurrence of depression, time to complete remission, time to major depressive disorder, time to recurrence of depression, number of major depressive episodes, number of recurrences and recurrence of depression per patient.
Secondary efficacy parameters were the change in the total number of major depressive episodes, time to complete remission, time to recurrence of depression, number of recurrences and recurrence of depression per patient.
GlaxoSmithKline, the world's largest manufacturer of prescription drugs, has agreed to a 30-year-deal with the pharmaceutical industry. It is forgoing all the major drugs for all its products, including those in pain, in order to focus on creating the best possible product for a patient's specific needs. The deal will be made in the UK and follows a three-year acquisition agreement with Glaxo.
GlaxoSmithKline
GSK
The merger will give it a more aggressive, long-term focus on the products that it will sell in the UK and in other countries in the US. In addition to its products, GlaxoSmithKline is also manufacturing its own generic versions of the prescription drugs Paxil and Wellbutrin.
The company was previously a research firm based in London and a research and development company based in the US.
The deal was announced in a press conference with CEO Cindy Whitehead. Whitehead said: "We are thrilled to have such a large presence in the UK and in the US. We are in a unique position in this industry, and the company has the right experience and expertise to grow and diversify its portfolio."
A spokeswoman for the company said: "We are pleased to have such a large presence in the UK.
GSK Pharmaceuticals has been an important player in the global pharmaceutical market for more than three decades. Its portfolio includes some of the most widely prescribed pharmaceuticals, such as the brand-name Paxil and generic versions of the widely used brand-name Paxil CR. It also has a portfolio of many branded products, including generics, which include a wide range of products such as the popular over-the-counter pain and anti-inflammatory drug Wex, the active ingredient in the brand-name Paxil.
The company was established in the UK in 1989 and grew rapidly when its manufacturing facilities began working on manufacturing new formulations of its popular brand-name drug Paxil. The company's UK operations now employs around 600 people worldwide. The company has a manufacturing base in the UK and a manufacturing site in the US.
Whitehead said: "We are pleased to have such a large presence in the UK and in the US. We are in a unique position in this industry, and the company has the right experience and expertise to grow and diversify its portfolio.
Alternate Name:Brisdelle
Description:Paxil CR is an antidepressant prescribed for the treatment of depression, anxiety disorders, and certain other conditions. The generic alternative is Paroxetine ER. The average Paxil CR cash pricing tends to be near $226 for a supply of 30, 20 mg Paxil CR controlled-release tablets. You can lower your Paxil cost by using our free Paxil CR coupon when you fill your prescription at a participating pharmacy near you.
Dosage Form:Tablet Extended Release 24 Hour
Administration Route:By mouth
Drug Class:Antidepressant, Central Nervous System Agent
Generic Available:Yes
Strength:25 MG
Warnings:It is not safe to take this medicine during pregnancy. It could harm an unborn baby. Tell your doctor right away if you become pregnant. Tell your doctor if you are breastfeeding, or if you have kidney disease, liver disease, sexual problems, glaucoma, or a history of epilepsy or seizures. For some children, teenagers, and young adults, this medicine may increase mental or emotional problems. This may lead to thoughts of suicide and violence. Talk with your doctor right away if you have any thoughts or behavior changes that concern you. Tell your doctor if you or anyone in your family has a history of bipolar disorder or suicide attempts. This medicine may cause the following problems: Serotonin syndrome (may be life-threatening when used with certain other medicines)Increased risk of bleeding problemsIncreased risk of broken bonesSexual problems Do not stop using this medicine suddenly. Your doctor will need to slowly decrease your dose before you stop it completely. This medicine may make you dizzy or drowsy. Do not drive or do anything that could be dangerous until you know how this medicine affects you. This medicine may decrease the amount of sperm men make and affect their ability to have children. If you plan to have children, talk with your doctor before using this medicine. Your doctor will do lab tests at regular visits to check on the effects of this medicine. Keep all appointments. Keep all medicine out of the reach of children. Never share your medicine with anyone.
Food Warnings:Do not use paroxetine and an MAO inhibitor (including isocarboxazid, linezolid, methylene blue, phenelzine, selegiline, tranylcypromine) within 14 days of each other. Do not use this medicine if you are using pimozide or thioridazine., Some medicines can affect how paroxetine works. Tell your doctor if you are using any of the following: Amitriptyline, atomoxetine, cimetidine, dextromethorphan, digoxin, fentanyl, fosamprenavir/ritonavir, meperidine, methadone, metoprolol, nebivolol, phenobarbital, phenytoin, procyclidine, risperidone, St John's wort, tamoxifen, theophylline, tolterodine, tramadolAmphetaminesBlood thinner (including clopidogrel, heparin, warfarin)Diuretic (water pill)Medicine for heart rhythm problems (including encainide, flecainide, propafenone, quinidine)NSAID pain or arthritis medicine (including aspirin, celecoxib, diclofenac, ibuprofen, naproxen)Other medicine for depression or anxiety (including buspirone, desipramine, fluoxetine, imipramine, lithium, nortriptyline, venlafaxine)Phenothiazine medicine (including chlorpromazine, perphenazine, prochlorperazine, promethazine)Triptan medicine for migraine headachesTryptophan supplements, Do not drink alcohol while you are using this medicine., This medicine may cause the following problems: Serotonin syndrome (may be life-threatening when used with certain other medicines)Low sodium levels in the bloodHigher risk of bleeding problemsHigher risk of broken bones, Do not stop using this medicine suddenly. Your doctor will need to slowly decrease your dose before you stop it completely., This medicine may make you dizzy or drowsy. Do not drive or do anything that could be dangerous until you know how this medicine affects you., Keep all medicine out of the reach of children.
This month's email address is.To the Editor,
The appropriate dosage of Paxil CR is determined by the doctor. However, there are no specific recommendations on how to take Paxil CR.
The doctor may instruct the patient to take Paxil CR with a meal or on an empty stomach. Taking Paxil CR with a meal or on an empty stomach may decrease the chance of experiencing nausea and vomiting. If you find that you experience nausea and vomiting while taking Paxil CR, consult your doctor as soon as possible.
Paxil CR can be taken with or without food. However, a meal may not increase the effects of Paxil CR.
The doctor may also instruct the patient to take Paxil CR with or without a meal. However, it is important to note that taking Paxil CR with a meal does not change the drug’s effect. For instance, if you experience nausea and vomiting while taking Paxil CR, consult your doctor for advice.
The following list contains side effects that patients should be aware of while taking Paxil CR.
Stade de France Pharmacy